Table 3.

Prespecified exploratory analyses from the PRIMA trial [11]

	PFS (mo)		HRa (95% CI)
Subgroup	NIR (n)	PL (n)
HRp	8.1 (169)	5.4 (80)	0.68 (0.49–0.94)
BRCA mutation HRd	22.1 (152)	10.9 (71)	0.40 (0.27–0.62)
Non-BRCA mutation HRd	19.6 (95)	8.2 (55)	0.50 (0.31–0.83)
Undetermined HRd status	NR (71)	NR (40)	0.85 (0.51–1.43)

HR hazard ratio, HRd patients who were homologous-recombination deficiency positive, HRp patients who were homologous-recombination deficiency negative, mo months, NIR niraparib, NR not reported, PFS progression-free survival, PL placebo

^aHR vs PL for disease progression or death